DSIP · Research brief

DSIP: Delta Sleep-Inducing Peptide Research Overview

Real Peptides Research TeamEditorial

Updated September 5, 202610 min read

48 WORDS

Short answer

DSIP, or delta sleep-inducing peptide, is a nine-amino-acid neuropeptide first isolated in the 1970s from the cerebral venous blood of rabbits in an induced sleep state. Laboratory research examines its reported influence on sleep architecture, stress-axis signaling, neuroprotection, and pain modulation. It is supplied for research use only.

Key takeaways

DSIP (delta sleep-inducing peptide) is a nonapeptide, sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, roughly 850 daltons, first isolated in the 1970s from cerebral venous blood of rabbits in an electrically induced sleep state.
No definitive DSIP receptor has been identified; a widely cited 2006 review in the Journal of Neurochemistry described the peptide as a still unresolved riddle, and that framing largely still holds.
Published work spans sleep and EEG models, stress and adaptation, neuroprotection after focal stroke in rats, seizure-model interactions, hepatocyte function under restraint stress, and delivery approaches such as blood-brain-barrier-crossing fusion constructs.
Evidence is dominated by rodent models and small, older clinical reports; findings remain preliminary and are not a basis for therapeutic conclusions.
DSIP is not an FDA-approved drug for any of the applications discussed here; material is supplied for laboratory research use only, not for human or veterinary use.
Supplier evaluation rests on batch-specific third-party COAs: HPLC purity, mass spectrometry identity near the expected mass, peptide content, and lot traceability.

What DSIP Is and Where It Came From

DSIP is a linear nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (single-letter: WAGGDASGE) and a molecular weight of roughly 850 daltons. It contains no cysteines and therefore no disulfide bridge, no basic residues, and a single tryptophan that provides weak ultraviolet absorbance useful for detection. The molecule is small, highly hydrophilic, and conformationally flexible in solution, which is one reason it has resisted straightforward structural characterization for five decades.

Its origin story is unusual and worth knowing, because it shapes how the peptide has been studied ever since. Working in Bern in the early 1970s, Monnier, Schoenenberger and colleagues perfused donor rabbits during electrical stimulation of the thalamus, collected cerebral venous dialysate, and reported that transferring that dialysate to recipient animals promoted delta-wave sleep. The active fraction was purified and sequenced, and the peptide was named for the phenomenon that led to its discovery rather than for a confirmed physiological function. That distinction matters: delta sleep-inducing peptide is a historical label, not a mechanistic description.

Subsequent immunoassay work described DSIP-like immunoreactivity in a wide range of tissues, including brain regions, the gastrointestinal tract, adrenal tissue, and plasma, with reported circadian variation. Whether that immunoreactivity reflects the identical nonapeptide, a family of related fragments, or cross-reacting sequences has never been fully settled, and the endogenous role of DSIP in mammals remains an open question.

One practical note for literature searches: the acronym DSIP is also used in analytical microbiology for deuterium stable isotope probing, as in a 2024 ACS Omega paper applying Raman deuterium stable isotope probing to antimicrobial mode-of-action studies in Escherichia coli. Database queries for DSIP therefore return two entirely unrelated literatures, and searches are cleaner when the full term delta sleep-inducing peptide is used.

Reported Mechanism of Action

There is no confirmed DSIP receptor. This is the single most important thing a researcher should understand before reading any secondary source that describes the peptide confidently. A frequently cited 2006 review in the Journal of Neurochemistry summarized the field under the title of a still unresolved riddle, and no subsequent work has displaced that assessment.

Several non-exclusive hypotheses appear across the literature, all of which should be treated as provisional:

Direct membrane interaction. Structure-function analyses of DSIP and its analogues, including work published in Bioorganicheskaia Khimiia, examined how the peptide and modified variants interact with cellular membranes, raising the possibility that some effects are mediated by lipid-bilayer association rather than by a classical G-protein-coupled receptor.
Neuromodulation rather than sedation. Reports describe influence on glutamatergic and GABAergic tone, opioid signaling, and somatostatin-related pathways. In contrast to sedative-hypnotics that act as direct positive allosteric modulators at GABA-A receptors, DSIP is generally characterized in the literature as modulatory, which is why mechanism comparisons with conventional sleep agents are treated separately in dedicated articles.
Stress-axis and adaptogenic effects. Russian-language and translated work, including reviews in Neuroscience and Behavioral Physiology, described DSIP and the DSIP-containing preparation Deltaran in the context of antistress protection, with proposed effects on corticosteroid responses and on antioxidant and membrane-stabilizing processes.
Fragment or downstream-cascade activity. Reported plasma clearance is rapid, on the order of minutes, while some described behavioral and physiological effects outlast that window. This mismatch has led to speculation that metabolites, fragments, or triggered downstream cascades carry the signal, though this remains hypothesis rather than demonstration.

What the Research Literature Examines

The published body of work is broad but shallow: many small studies across many endpoints, mostly in animals, often decades old, and rarely replicated by independent groups under modern standards. The areas below reflect where investigation has actually concentrated.

Sleep and EEG models

Sleep remains the peptide's namesake area. Early work reported changes in slow-wave and delta activity in animal recordings, and small early clinical reports examined subjective and polysomnographic sleep measures in human volunteers and in insomnia and chronic-pain populations. Those human studies were generally small, methodologically heterogeneous, and inconsistently controlled, so evidence remains preliminary. More recent work approaches the question from a delivery angle: a 2024 paper in Frontiers in Pharmacology described Pichia pastoris-secreted peptides engineered to cross the blood-brain barrier and evaluated a DSIP fusion peptide in a PCPA-induced insomnia mouse model, an approach that reflects the field's shift toward constructs designed to solve the peptide's delivery and stability limitations.

Stress, adaptation, and peripheral organ responses

A substantial line of investigation, largely from Russian laboratories, examines DSIP as an antistress or adaptogenic agent. A 2016 report in the Bulletin of Experimental Biology and Medicine examined the functional state of hepatocytes in rats subjected to restraint stress, illustrating that this literature extends well beyond the central nervous system into peripheral tissue responses under stress load. Reviews in this tradition frame DSIP as a modulator of stress resistance rather than as a hypnotic.

Neuroprotection and seizure models

A 2021 study in Molecules reported recovery of motor function in Sprague-Dawley rats following focal stroke, positioning DSIP within neuroprotection and recovery research. Separately, a 2007 paper in Cellular and Molecular Neurobiology examined the interaction of DSIP with valproate in the metaphit audiogenic seizure model in rats, an example of the peptide being studied as a potential modifier of another agent's activity rather than in isolation. Both lines are preclinical, and neither supports conclusions about human outcomes.

Comparative and pharmacokinetic questions

Because DSIP is frequently compared with conventional sleep agents, a large share of practical interest concerns how its reported mechanism differs from GABA-A-targeting hypnotics or from melatonin's chronobiotic signaling, and how its rapid clearance shapes experimental design. Those comparisons and pharmacokinetic details are treated in depth in separate articles in this collection.

Laboratory Handling: Reconstitution and Storage

DSIP is typically supplied as a lyophilized powder in a sealed vial. General laboratory practice for small hydrophilic peptides applies, and specific volumes, concentrations, and calculations are covered in dedicated handling guides rather than here.

Lyophilized state. Sealed vials are generally kept cold and dark, with freezer storage used for longer holding periods. Vials are commonly allowed to equilibrate toward room temperature before opening to limit condensation onto the cake.
Reconstitution. Diluent is usually introduced slowly down the inner wall of the vial rather than directly onto the powder, and the vial is swirled or left to dissolve rather than shaken, since vigorous agitation can shear and aggregate peptides.
Visual inspection. A properly reconstituted preparation is typically clear and colorless. Cloudiness, visible particulate, or persistent undissolved material is treated as a reason to discard rather than to proceed.
Post-reconstitution storage. Solutions are refrigerated, protected from light, and often aliquoted so that repeated freeze-thaw cycles are avoided. Solution-state stability is shorter than lyophilized stability, and working solutions are dated on the label.
Documentation. Recording lot number, diluent, date of reconstitution, and storage location keeps results traceable to a specific batch and its COA.

Regulatory and Research-Use Status

DSIP is not an FDA-approved drug for sleep, stress, neuroprotection, or any other application discussed on this page. It is not an approved veterinary product and is not a dietary supplement ingredient. It has never completed the modern regulatory pathway of adequate and well-controlled trials that would support therapeutic claims, and the older clinical literature does not meet that standard.

Material offered by research suppliers, including Real Peptides, is intended for laboratory research use only, by qualified personnel, in appropriate institutional settings. It is not intended for human or animal consumption, for diagnostic use, or for any clinical application. Investigators are responsible for the institutional approvals, biosafety review, and local regulations that govern their own work.

How Researchers Evaluate Supplier Quality

Because DSIP is a small peptide with no distinctive chromophore beyond a single tryptophan and no widely available reference assay in most labs, documentation is the practical basis for confidence in a batch. The following is the minimum a serious buyer should expect.

Analysis	What it establishes	What to look for
HPLC purity	Proportion of the target peptide relative to related impurities	A printed chromatogram, not just a stated number; research-grade material is commonly specified at 98 percent or higher
Mass spectrometry	Identity confirmation of the intended sequence	An observed mass consistent with the nonapeptide near 850 daltons, with the spectrum included
Peptide content	How much of the vial mass is peptide versus water, salts, and counterion	A content figure or the method used, since net weight alone overstates peptide mass
Batch traceability	That the COA corresponds to the vial in hand	A lot number on both the vial label and the certificate, published per batch
Third-party testing	Independence from the manufacturer's own quality claims	An external laboratory named on the report, with test dates

Beyond the paperwork, sensible checks include confirming that appearance matches expectation for a lyophilized peptide, that vials are properly sealed and labeled, and that cold-chain handling was used where the supplier specifies it. A supplier that publishes COAs per batch, rather than a single representative certificate reused across lots, is making a meaningfully stronger commitment.

Where the Open Questions Are

DSIP is best understood as an unfinished research problem rather than a characterized tool compound. The most consequential gaps are these. First, the receptor question: without an identified binding target, mechanistic claims rest on downstream observations and remain interpretive. Second, the endogenous-function question: DSIP-like immunoreactivity is widely distributed, but whether the nonapeptide itself is the physiologically relevant species is unresolved. Third, the pharmacokinetic paradox: rapid reported clearance sits uneasily beside effects described as longer-lasting, and no mechanism reconciling the two has been established.

Fourth, the reproducibility question: much of the supporting literature comes from a limited number of groups, some of it published decades ago in journals with limited international circulation, and independent replication under modern blinding and preregistration standards is largely absent. Fifth, delivery: the peptide's size and hydrophilicity make central exposure a genuine obstacle, which is precisely why recent work has explored fusion constructs designed to cross the blood-brain barrier.

For researchers, that combination of persistent interest and thin mechanistic foundation is the honest summary. The remaining articles in this collection go deeper on individual questions, comparative pharmacology, handling procedure, and stability, each written for the same laboratory context that governs this hub.

Research-grade DSIP: Real Peptides supplies DSIP for laboratory research with a published third-party Certificate of Analysis for every batch. Research use only.

Explore DSIP research on Real Peptides

The articles below go deeper on the questions researchers ask most about DSIP.

Research timelines & mechanisms

Reconstitution, storage & handling

Stacks & comparisons

Research questions

Buying & quality

Safety & side effects

DSIP Side Effects Long Term Research — What Science Shows

Legal & regulatory

Is DSIP FDA Approved Status? (Regulatory Facts)

References

Peer-reviewed sources on DSIP indexed in PubMed, listed for research context. Real Peptides supplies DSIP for laboratory research use only.

Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models. Frontiers in pharmacology, 2024. PMID 39444618. doi:10.3389/fphar.2024.1439536
Sensing the Bactericidal and Bacteriostatic Antimicrobial Mode of Action Using Raman Deuterium Stable Isotope Probing (DSIP) in Escherichia coli. ACS omega, 2024. PMID 38854576. doi:10.1021/acsomega.4c01666
Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke. Molecules (Basel, Switzerland), 2021. PMID 34500605. doi:10.3390/molecules26175173
Effect of Delta Sleep-Inducing Peptide on Functional State of Hepatocytes in Rats During Restraint Stress. Bulletin of experimental biology and medicine, 2016. PMID 26902351. doi:10.1007/s10517-016-3186-8
Delta sleep-inducing peptide and Deltaran: potential approaches to antistress protection. Neuroscience and behavioral physiology, 2008. PMID 18975104. doi:10.1007/s11055-008-9076-4
Interaction of Delta sleep-inducing peptide and valproate on metaphit audiogenic seizure model in rats. Cellular and molecular neurobiology, 2007. PMID 17957464. doi:10.1007/s10571-007-9222-5
Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of neurochemistry, 2006. PMID 16539679. doi:10.1111/j.1471-4159.2006.03693.x
[Interaction of delta sleep-inducing peptide and its analogues with cellular membranes: a structure-function analysis]. Bioorganicheskaia khimiia, 2006. PMID 16637289. doi:10.1134/s1068162006020087

Questions

DSIP stands for delta sleep-inducing peptide. It is a linear nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, written WAGGDASGE in single-letter code, and a molecular weight of approximately 850 daltons. It contains no cysteine residues and therefore no disulfide bond. The name reflects the sleep phenomenon observed during its 1970s isolation, not a confirmed physiological mechanism.

No. DSIP is not an FDA-approved drug for sleep, stress, neuroprotection, or any other application, and it is not an approved veterinary product or dietary supplement ingredient. The existing human literature consists largely of small, older reports that do not meet modern standards for adequate and well-controlled trials. Material from research suppliers is intended for laboratory research use only.

Not definitively. Despite decades of investigation, no confirmed receptor has been characterized. A widely cited 2006 review in the Journal of Neurochemistry described DSIP as a still unresolved riddle, and that assessment largely stands. Proposed alternatives include direct interaction with cellular membranes, examined in structure-function studies of DSIP analogues, and indirect modulation of glutamatergic, GABAergic, opioid, and stress-axis signaling.

Because the acronym is shared. In analytical microbiology, DSIP also denotes deuterium stable isotope probing, as in a 2024 ACS Omega study using Raman deuterium stable isotope probing to assess antimicrobial mode of action in Escherichia coli. Searching the full term delta sleep-inducing peptide, or pairing DSIP with terms such as neuropeptide or sleep, filters out the unrelated literature.

Published work extends into stress and adaptation research, including a 2016 report on hepatocyte function in rats under restraint stress; neuroprotection, including a 2021 study reporting motor recovery in rats after focal stroke; and seizure-model pharmacology, including work on DSIP and valproate in an audiogenic seizure model. All of these are preclinical, and the evidence remains preliminary.

A batch-specific COA from an independent laboratory should include an HPLC chromatogram supporting the stated purity, a mass spectrometry spectrum consistent with the expected nonapeptide mass near 850 daltons, an indication of peptide content versus net vial weight, test dates, and a lot number matching the vial label. Certificates published per batch are stronger than a single representative document reused across lots.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA